Whalen Wealth Management Inc. acquired a new stake in Natera, Inc. (NASDAQ:NTRA – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,967 shares of the medical research company’s stock, valued at approximately $534,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Integrated Wealth Concepts LLC raised its position in shares of Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 96 shares during the last quarter. NewEdge Advisors LLC boosted its position in shares of Natera by 68.3% in the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after purchasing an additional 1,847 shares during the last quarter. Focus Partners Wealth grew its stake in shares of Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after purchasing an additional 474 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of Natera during the second quarter worth $298,000. Finally, WINTON GROUP Ltd bought a new stake in Natera in the second quarter valued at about $558,000. 99.90% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
NTRA has been the topic of several analyst reports. Zacks Research raised Natera from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Wells Fargo & Company boosted their target price on Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Royal Bank Of Canada increased their price target on shares of Natera from $275.00 to $350.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. Wall Street Zen cut shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, BTIG Research upped their target price on shares of Natera from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $319.38.
Natera Stock Down 1.3%
Natera stock opened at $327.72 on Tuesday. The stock has a market capitalization of $47.24 billion, a PE ratio of -240.97 and a beta of 1.51. Natera, Inc. has a twelve month low of $157.43 and a twelve month high of $333.56. The company has a 50 day moving average of $276.45 and a 200-day moving average of $230.09.
Natera (NASDAQ:NTRA – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm’s quarterly revenue was up 37.7% on a year-over-year basis. During the same period last year, the business posted ($0.74) earnings per share. Equities analysts anticipate that Natera, Inc. will post -1.02 EPS for the current fiscal year.
Insider Activity
In other Natera news, Director Herm Rosenman sold 16,530 shares of the stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the completion of the transaction, the director owned 4,250 shares in the company, valued at approximately $1,062,500. This represents a 79.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the sale, the chief executive officer directly owned 108,743 shares in the company, valued at $24,035,465.29. This represents a 27.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 177,955 shares of company stock worth $40,704,193. 5.05% of the stock is currently owned by insiders.
Natera Profile
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Articles
- Five stocks we like better than Natera
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
